The National Eye Institute (NEI) awarded a $774,169 Project Grant under the Vision Research program (CFDA 93.867) to The Trustees of Columbia University in the City of New York to advance the development of a small molecule drug candidate as a therapy for dry age-related macular degeneration (dry AMD). The proposed research objectives are to: 1) perform experiments required to progress the drug candidate, (R)-ACPHS-62, towards IND-enabling studies, and 2) conduct the necessary GLP-compliant IND-enabling studies and submit the IND application. Dry AMD is a leading cause of blindness in the United States, and the drug candidate aims to inhibit the synthesis of lipofuscin bisretinoids, which accumulate in the retina and contribute to the pathogenesis of dry AMD. The federal grant funding will support activities at Columbia University's Health Sciences Division, a private non-profit research organization, from July 2024 through June 2026.
Generated 3/4/25, 6:25 AM